FindTrial
Sign In

Effect of patient-controlled analgesia with oxycodone or sufentanil combined with quadratus lumborum block or transverse abdominis plane block on recovery after laparoscopic major gastrointestinal surgery: A randomized, controlled, factorial clinical trial

Effect of patient-controlled analgesia with oxycodone or sufentanil combined with quadratus lumborum block or transverse abdominis plane block on recovery after laparoscopic major gastrointestinal surgery: A randomized, controlled, factorial clinical trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400080766
Enrollment
Unknown
Registered
2024-02-06
Start date
2024-03-01
Completion date
Unknown
Last updated
2024-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative recovery

Interventions

Oxycodone combined with quadratus lumborum block group:Oxycodone + bilateral quadratus lumborum block
Oxycodone combined with transverse abdominis plane block group:Oxycodone + bilateral transverse abdominis plane block
Sufentanil combined with quadratus lumborum block group:Sufentanil + bilateral quadratus lumborum block.
Sufentanil combined with transverse abdominis plane block group:Sufentanil + bilateral transverse abdominis plane block

Sponsors

Department of Anesthesiology, First Affiliated Hospital of Soochow University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age =18 years old, male or female sex; American classification of anesthesiologists (ASA) grades I-III; undergoing laparoscopic major gastrointestinal cancer surgery under general anesthesia (surgery time =2 h); providing written inform consent.

Exclusion criteria

Exclusion criteria: Unplanned or emergency surgery; BMI=35 kg/m2; Allergy to the drug under study; Severe cardiopulmonary diseases (myocardial infarction, heart failure, respiratory failure); Severe cerebrovascular diseases (cerebral hemorrhage, stroke); Severe liver and kidney function diseases (Child-Pugh C grade, renal replacement therapy); Serious nervous system diseases (Parkinson's disease, Alzheimer's disease), use of antipsychotics, alcoholism, long-term use of opioids or other analgesic drugs; Those who are unable to communicate, declined to use PCIA, and unable to understand postoperative recovery scale and pain score scale.

Design outcomes

Primary

MeasureTime frame
QoR-15 score at 24 hours after surgery;—

Secondary

MeasureTime frame
Visceral pain scores;Incisional pain scores;postoperative analgesic consumption;QoR-15 recovery score;Remedial analgesia and analgesic dosage;Postoperative flatus time;Length of postoperative hospital stay;Sedation score;Nausea and vomiting;Use of antiemetics;Respiratory depression;Dizziness;—

Countries

China

Contacts

Public ContactPeng Ke

The First Affiliated Hospital of Soochow University

pengke0422@163.com+86 159 6215 5989

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 5, 2026